Etravirine
- Generic Name
- Etravirine
- Brand Names
- Intelence
- Drug Type
- Small Molecule
- Chemical Formula
- C20H15BrN6O
- CAS Number
- 269055-15-4
- Unique Ingredient Identifier
- 0C50HW4FO1
- Background
Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HI...
- Indication
Etravirine is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in treatment-experienced patients ≥2 years of age.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
- First Posted Date
- 2009-09-21
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 180
- Registration Number
- NCT00980538
Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study
- Conditions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 28
- Registration Number
- NCT00871234
- Locations
- 🇺🇸
Infectious Diseases Research Center, Indianapolis, Indiana, United States
GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir
- Conditions
- Interventions
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 17
- Registration Number
- NCT00867152
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
- Conditions
- Interventions
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 77
- Registration Number
- NCT00855335
Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue
- Conditions
- Interventions
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2011-05-13
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 13
- Registration Number
- NCT00855088
- Locations
- 🇺🇸
UNC Hospitals CTRC, Chapel Hill, North Carolina, United States
HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine
- Conditions
- Interventions
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 15
- Registration Number
- NCT00855413
- Locations
- 🇺🇸
The University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸Duke University, Durham, North Carolina, United States
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1
- Conditions
- Interventions
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 105
- Registration Number
- NCT00823979
- Locations
- 🇧🇷
Hospital Nossa Senhora da Conceicao, PoA, RS, Brazil
🇺🇸Hillsborough County Health Department, Tampa, Florida, United States
🇺🇸Ruth M. Rothstein CORE Center, Chicago, Illinois, United States
Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz
- First Posted Date
- 2008-11-18
- Last Posted Date
- 2011-09-12
- Lead Sponsor
- University Hospital, Geneva
- Target Recruit Count
- 50
- Registration Number
- NCT00792584
- Locations
- 🇨🇭
Geneva Hospital, Geneva, Switzerland
Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2009-11-18
- Lead Sponsor
- St Stephens Aids Trust
- Target Recruit Count
- 24
- Registration Number
- NCT00792324
- Locations
- 🇬🇧
Chelsea and Westminster Hospital, London, United Kingdom
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- ViiV Healthcare
- Registration Number
- NCT00782301
- Locations
- 🇵🇱
Pfizer Investigational Site, Bydgoszcz, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.